ZVRA ZEVRA THERAPEUTICS, INC.

Nasdaq kempharm.com


$ 10.33 $ 0.00 (0 %)    

Thursday, 30-Oct-2025 04:00:01 EDT
QQQ $ 635.40 $ 0.00 (0 %)
DIA $ 475.57 $ 0.00 (0 %)
SPY $ 686.87 $ 0.00 (0 %)
TLT $ 90.86 $ 0.00 (0 %)
GLD $ 365.34 $ 0.00 (0 %)
$ 10.12
$ 11.12
$ 10.12 x 1
$ 10.65 x 100
-- - --
$ 6.19 - $ 13.16
1,551,409
na
568.09M
$ 4.26
$ 214.86
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-12-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 04-01-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-07-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-12-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-30-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-13-2021 06-30-2021 10-Q
18 05-13-2021 03-31-2021 10-Q
19 03-12-2021 12-31-2020 10-K
20 10-30-2020 09-30-2020 10-Q
21 08-12-2020 06-30-2020 10-Q
22 05-13-2020 03-31-2020 10-Q
23 02-28-2020 12-31-2019 10-K
24 11-14-2019 09-30-2019 10-Q
25 08-13-2019 06-30-2019 10-Q
26 05-14-2019 03-31-2019 10-Q
27 03-01-2019 12-31-2018 10-K
28 11-09-2018 09-30-2018 10-Q
29 08-10-2018 06-30-2018 10-Q
30 05-11-2018 03-31-2018 10-Q
31 03-30-2018 12-31-2017 10-K
32 11-09-2017 09-30-2017 10-Q
33 08-10-2017 06-30-2017 10-Q
34 05-22-2017 03-31-2017 10-Q
35 03-10-2017 12-31-2016 10-K
36 11-10-2016 09-30-2016 10-Q
37 08-11-2016 06-30-2016 10-Q
38 05-13-2016 03-31-2016 10-Q
39 03-16-2016 12-31-2015 10-K
40 11-13-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-pepgen-shares-are-trading-higher-by-112-here-are-20-stocks-moving-premarket

Shares of PepGen Inc. (NASDAQ: PEPG) rose sharply in pre-market trading after the company announced the launch of an underwritt...

 zevra-therapeutics-presents-several-posters-highlighting-new-data-on-miplyffa-for-treatment-of-niemann-pick-disease-type-c-at-iciem

New data from pre-specified analysis shows patients on concomitant miglustat who switched from placebo to MIPLYFFA experienced ...

 zevra-therapeutics-to-present-four-posters-on-miplyffa-at-iciem-2025

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for p...

 jmp-securities-maintains-market-outperform-on-zevra-therapeutics-lowers-price-target-to-18

JMP Securities analyst Jason N. Butler maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Market Outperform and lowers the pr...

 zevra-therapeutics-q2-eps-124-beats-113-estimate-sales-2590m-beat-2249m-estimate

Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly earnings of $1.24 per share which beat the analyst consensus estimate of $1...

 zevra-therapeutics-has-submitted-a-marketing-authorization-application-to-the-european-medicines-agency-for-the-evaluation-of-arimoclomol-for-niemann-pick-disease-type-c

The EMA will review the application under the centralized marketing authorization procedure. If a marketing authorization is gr...

 zevra-therapeutics-to-present-three-posters-on-miplyffa-and-one-on-olpruva-annual-sergg-2025

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for p...

 cantor-fitzgerald-maintains-overweight-on-zevra-therapeutics-raises-price-target-to-29

Cantor Fitzgerald analyst Kristen Kluska maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Overweight and raises the price t...

 how-zevras-miplyffa-could-transform-investment-strategies

HC Wainwright sees Zevra's Miplyffa launch and EU plans driving upside, initiating coverage with a $26 target and Buy ratin...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION